A synthetic tanning peptide designed at the University of Arizona in the 1980s—tested in human volunteers, proven to darken skin, and eventually approved by the FDA as afamelanotide for a rare genetic disease

In the 1980s, two University of Arizona researchers—peptide chemist Victor Hruby and pharmacologist Mac Hadley—set out to create a tanning pill. Their reasoning was straightforward: if you could stimulate the skin to produce protective melanin without UV radiation, you could reduce skin cancer risk. They designed two synthetic analogs of alpha-MSH, the body's natural melanocyte-stimulating hormone. The first, a linear 13-amino-acid peptide, became Melanotan I. The second, a cyclic 7-amino-acid peptide, became Melanotan II.

Melanotan I's path was the legitimate one. It entered Phase I clinical trials at the University of Arizona, where subcutaneous injections safely produced visible skin darkening in fair-skinned volunteers. The compound was licensed to Clinuvel Pharmaceuticals, reformulated as a slow-release subcutaneous implant, renamed afamelanotide, and pivoted from cosmetic tanning to the treatment of erythropoietic protoporphyria (EPP)—a rare genetic condition that makes sunlight excruciatingly painful. The FDA approved Scenesse in October 2019.

This article covers Melanotan I as a research compound—the Phase I data generated under that name at the University of Arizona. For the approved drug, see the separate afamelanotide article on Peptidings.

Quick Facts: Melanotan I at a Glance

What Is Melanotan I?

Pronunciation: MEL-ah-no-tan ONE

Your skin darkens in sunlight because ultraviolet radiation triggers a signaling cascade: UV hits keratinocytes → keratinocytes release alpha-MSH → alpha-MSH binds MC1R on melanocytes → melanocytes produce eumelanin (dark, photoprotective pigment). Melanotan I is a synthetic shortcut. It activates MC1R directly, bypassing the UV trigger entirely—producing tanning without the DNA damage that UV causes.

The Design

Victor Hruby and Mac Hadley made two specific amino acid substitutions to the natural alpha-MSH sequence. They replaced methionine at position 4 with norleucine (preventing oxidative degradation) and swapped L-phenylalanine at position 7 for D-phenylalanine (increasing potency 100-fold and extending duration of action 1,000-fold). The result was a superpotent, metabolically stable MC1R agonist.

Not Melanotan II

Melanotan I and Melanotan II are different compounds. MT-I is a linear 13-amino-acid peptide that primarily activates MC1R (the pigmentation receptor). MT-II is a cyclic 7-amino-acid peptide that activates multiple melanocortin receptors non-selectively (MC1R, MC3R, MC4R, MC5R), causing tanning plus nausea, erectile effects, and appetite suppression. MT-II is widely available on the unregulated peptide market and has never been approved. MT-I became an FDA-approved drug. The distinction matters.

Origins and Discovery

The University of Arizona Tanning Project

The Melanotan program originated from a collaboration between Victor Hruby (Department of Chemistry) and Mac Hadley (Department of Cell Biology and Anatomy) at the University of Arizona in the early 1980s. Their goal was a "barbie drug"—a peptide that could safely darken skin for cosmetic and photoprotective purposes.

Arizona was an appropriate birthplace. The state has among the highest rates of skin cancer in the United States, driven by intense UV exposure and a largely fair-skinned population. Hruby and Hadley hypothesized that a potent MC1R agonist could stimulate eumelanin production—the dark, protective form of melanin—reducing UV damage and potentially lowering skin cancer risk.

The program produced two compounds. MT-I, the linear analog, became the basis for legitimate pharmaceutical development. MT-II, the cyclic analog, became one of the most widely used unregulated peptides in the tanning community—and one of the most discussed compounds in peptide biohacking forums. The two compounds share a parent laboratory but diverged dramatically in their subsequent paths.

From Research to Clinuvel

Clinuvel Pharmaceuticals (then Epitan, Melbourne, Australia) licensed the Melanotan I compound, reformulated it as a 16 mg biodegradable subcutaneous implant to overcome the short half-life, and pivoted the indication from cosmetic tanning to the orphan disease erythropoietic protoporphyria. This repositioning—from vanity product to life-changing rare disease treatment—is one of the most successful examples of drug repositioning in peptide medicine.

Mechanism of Action

MC1R Activation and Melanogenesis

Melanotan I binds MC1R on melanocytes with high affinity, triggering the canonical pigmentation cascade:

1. MC1R activation → Gs protein → adenylyl cyclase → cAMP 2. cAMP → protein kinase A (PKA) → CREB phosphorylation 3. CREB → MITF (microphthalmia-associated transcription factor) transcription 4. MITF → upregulation of tyrosinase, TRP-1, and DCT (melanogenic enzymes) 5. Enzymatic conversion of L-DOPA → eumelanin (dark, photoprotective pigment)

Eumelanin vs. Pheomelanin

The distinction matters. There are two types of melanin: eumelanin (dark brown/black, photoprotective, absorbs UV) and pheomelanin (red/yellow, phototoxic, generates reactive oxygen species upon UV exposure). MC1R activation shifts melanocyte production toward eumelanin and away from pheomelanin. This is pharmacologically desirable—more protection, less damage.

UV Synergy

Dorr et al. (2004; PMID 15262693) demonstrated that MT-I combined with controlled UV-B exposure produced synergistic tanning—the combination was more effective than either alone. Histological analysis confirmed that the induced pigment was eumelanin, not pheomelanin, confirming the photoprotective intent.

Key Research Areas and Studies

First Human Trial (Levine et al., 1991)

Levine et al. (PMID 2008047) conducted the first human administration of Melanotan I in six fair-skinned male volunteers. Subcutaneous injections produced dose-dependent skin darkening measured by reflectance spectrophotometry. The primary side effect was nausea at higher doses. This proof-of-concept study established that a synthetic melanocortin analog could safely induce melanogenesis in humans—a pivotal finding for the entire field.

Pharmacokinetics (Dorr et al., 2000)

Dorr et al. (PMID 10626131) characterized MT-I pharmacokinetics: half-life approximately 30 minutes after subcutaneous injection, with dose-dependent skin pigmentation. The short half-life was the major challenge for clinical development—daily injections were impractical for a photoprotection product—and directly motivated the development of the depot implant formulation used by Clinuvel.

UV Combination Study (Dorr et al., 2004)

Dorr et al. (PMID 15262693) enrolled 65 subjects and demonstrated that MT-I combined with solar UV radiation produced synergistic tanning. Histological confirmation of eumelanin induction provided the scientific basis for the photoprotection claim that would ultimately drive the EPP indication.

Claims vs. Evidence

The Human Evidence Landscape

Melanotan I has Phase I human data from three University of Arizona studies—among the earliest human clinical data for any synthetic melanocortin peptide.

Levine et al., 1991 (PMID 2008047)

Design. Open-label Phase I. Six fair-skinned male volunteers. Subcutaneous MT-I injection.

Results. Dose-dependent skin darkening confirmed by reflectance spectrophotometry. Nausea was the dose-limiting adverse event at higher doses. No serious adverse events.

Significance. First demonstration that a synthetic melanocortin analog could safely induce human melanogenesis. Proof-of-concept for the entire melanocortin tanning field.

Dorr et al., 2000 (PMID 10626131)

Design. Phase I pharmacokinetic study. 12 subjects. SC MT-I at multiple dose levels.

Results. Half-life approximately 30 minutes. Dose-dependent pigmentation. PK profile established.

Significance. Identified the short half-life as the primary pharmacokinetic challenge, motivating the depot implant development.

Dorr et al., 2004 (PMID 15262693)

Design. Phase I. 65 subjects. MT-I ± solar UV radiation.

Results. Synergistic tanning with UV combination. Histological confirmation of eumelanin induction (photoprotective melanin type). MT-I alone produced moderate tanning; MT-I + UV produced significantly more.

Significance. Largest Phase I dataset for MT-I. Confirmed eumelanin specificity—the induced pigment is the protective type, not the phototoxic type.

Safety, Risks, and Limitations

Phase I Safety Profile

• Nausea: The most common side effect and dose-limiting at higher doses. Typically transient.
• Facial flushing: Mild, self-resolving.
• Injection site reactions: Mild irritation at injection sites.
• Nevi darkening: Existing moles became darker during treatment. This raised theoretical concerns about melanocyte stimulation in pre-malignant lesions.
• No serious adverse events in any Phase I trial.

Melanoma Monitoring Concern

Darkening of nevi was observed consistently across Phase I studies. While no melanoma has been causally linked to MT-I or afamelanotide in clinical trials or post-marketing surveillance, the theoretical concern remains. Any compound that stimulates melanocyte proliferation and pigmentation warrants long-term melanoma surveillance. Afamelanotide's REMS program includes dermatological monitoring recommendations.

Vendor-Sourced MT-I Risks

Research-grade MT-I from peptide vendors is not pharmaceutical grade. Risks include: impurities, incorrect peptide content, non-sterile preparation, and lack of quality control. The FDA-approved form (Scenesse implant) undergoes pharmaceutical manufacturing standards. The two are not interchangeable from a safety perspective.

Legal and Regulatory Status

FDA Status

Melanotan I (research designation): Not FDA-approved. The identical molecule, afamelanotide, is FDA-approved as Scenesse for EPP (October 2019). Available only through REMS.

Research Peptide Status

MT-I is available from research peptide vendors as "Melanotan I" or "[Nle⁴,D-Phe⁷]-α-MSH." It is sold for research purposes. Self-administration of research-grade peptides is not FDA-regulated but is not endorsed by any medical authority.

WADA Status

Not on the Prohibited List. However, detection methods for melanocortin peptides exist.

Melanotan II Distinction

MT-II is frequently confused with MT-I in public discussion. They are different compounds with different receptor profiles, different side effect profiles, and different regulatory histories. MT-II has never entered legitimate clinical development.

Research Protocols and Formulation Considerations

Phase I Formulation

MT-I was administered as reconstituted lyophilized peptide via subcutaneous injection in Phase I trials. Standard peptide reconstitution with sterile water or bacteriostatic water.

Commercial Formulation (Afamelanotide)

The 16 mg biodegradable PLGA (poly-lactic-co-glycolic acid) subcutaneous implant provides sustained release over approximately 60 days. This elegant formulation solved the 30-minute half-life problem—instead of daily injections, patients receive one implant every two months.

Research Vendor Formulation

Vendor-sourced MT-I is typically supplied as lyophilized powder requiring reconstitution. Purity, sterility, and accurate peptide content are not guaranteed to pharmaceutical standards.

Dosing in Published Research

The following table summarizes dosing protocols for Melanotan I as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Phase I Dosing

• Levine et al., 1991: Dose-escalation, subcutaneous
• Dorr et al., 2000: 0.16 mg/kg SC daily × 10 days
• Dorr et al., 2004: Doses producing skin darkening combined with UV

Commercial Dosing (Afamelanotide/Scenesse)

16 mg subcutaneous implant every 60 days. Administered by healthcare provider.

Community Dosing Context

Research-grade MT-I is available from peptide vendors, though it is far less commonly self-administered than Melanotan II. Community protocols (when used) typically follow dose ranges similar to the Phase I studies. MT-I requires more frequent dosing than MT-II due to its short half-life.

Dosing in Self-Experimentation Communities

Melanotan I has a small presence in the peptide self-experimentation community, but it is vastly overshadowed by Melanotan II. The reasons are practical: MT-I has a 30-minute half-life requiring frequent injections, produces slower visible tanning, and is more expensive per effective dose than MT-II. Most community tanning protocols use MT-II, not MT-I.

When MT-I is self-administered, community protocols generally follow subcutaneous injection at doses in the range of 0.5–1.0 mg daily, consistent with the Phase I dosing framework. No controlled study has evaluated the safety of long-term self-administration outside of clinical trial settings.

Combination Stacks

Research into Melanotan I combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Melanotan I with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Compound	Type	Evidence Tier	Verdict	Primary Receptor	Primary Mechanism	Primary Application	Human Data	FDA Status	WADA Status	Key Limitation
Alpha-MSH	Endogenous tridecapeptide (13 aa, POMC-derived)	Tier 4 — Preclinical Only	Eyes Open	MC1R (non-selective across MC1/3/4/5)	MC1R → melanogenesis; NF-κB suppression → anti-inflammatory	Pigmentation (endogenous); anti-inflammatory (endogenous)	None therapeutic	Not developed (analogs approved)	Not prohibited	Half-life ~10 min; non-selective; not a drug candidate
Melanotan I	Synthetic linear tridecapeptide α-MSH analog	Tier 2 — Clinical Trials	Reasonable Bet	MC1R	MC1R agonist → eumelanin synthesis (100× potency vs α-MSH)	Photoprotective tanning; precursor to afamelanotide	Phase I (N=83); dose-dependent tanning	Not approved (became afamelanotide)	Not prohibited	Short half-life (~30 min); superseded by afamelanotide depot
Afamelanotide	Synthetic tridecapeptide (16 mg SC implant)	Tier 1 — Approved Drug	Strong Foundation	MC1R	MC1R → eumelanin synthesis + DNA repair enhancement	EPP phototoxicity prevention; vitiligo (Phase II)	Phase III RCT (N=74); long-term N=115; vitiligo N=55	Approved October 2019 (Scenesse) for EPP	Not prohibited	Restricted to EPP (REMS); nevi darkening; melanoma monitoring
Setmelanotide	Synthetic cyclic octapeptide MC4R agonist	Tier 1 — Approved Drug	Strong Foundation	MC4R	MC4R → hypothalamic satiety signaling restoration	Monogenic obesity (POMC/PCSK1/LEPR/BBS deficiency)	Phase 3 (N=21 POMC/LEPR; N=32 BBS; N=18 VENTURE)	Approved November 2020 (IMCIVREE)	Not prohibited	Only works for genetically confirmed MC4R pathway defects; hyperpigmentation (78%)
ACTH	39 aa polypeptide (porcine pituitary, gelatin depot)	Tier 1 — Approved Drug	Reasonable Bet	MC2R (primary); MC1/3/5R (secondary)	MC2R → adrenal cortisol; MCR → immunomodulation	Infantile spasms; MS exacerbation; nephrotic syndrome	RCTs (N=107 IS; N=197 MS); decades of clinical use	Approved 1952 (H.P. Acthar Gel)	Prohibited (S2)	~$38K/vial pricing controversy; limited modern RCTs for most indications
PL-8177	Synthetic selective MC1R agonist (oral formulation)	Tier 2 — Clinical Trials	Reasonable Bet	MC1R	MC1R → anti-inflammatory (NF-κB suppression in gut mucosa)	Ulcerative colitis; IBD	Phase 2 RCT (~N=60; 33% remission vs 0% placebo)	Not approved (Phase 2 complete)	Not prohibited	Phase 3 needed; full data not yet published

Frequently Asked Questions

Summary of Key Findings

Melanotan I is a synthetic alpha-MSH analog designed at the University of Arizona in the 1980s to produce sunless tanning. Phase I clinical trials in approximately 83 volunteers demonstrated safe, dose-dependent skin darkening via eumelanin induction. The compound was licensed to Clinuvel Pharmaceuticals, reformulated as a subcutaneous implant, and approved by the FDA in 2019 as afamelanotide (Scenesse) for erythropoietic protoporphyria.

The MT-I research program represents one of the few successful translations from university peptide research to FDA-approved drug. The scientific concept—MC1R agonism for photoprotection—was validated in humans and withstood the full rigor of pharmaceutical development. Side effects (nausea, nevi darkening) are manageable and monitored.

Verdict Recapitulation

The Reasonable Bet verdict for Melanotan I reflects the validated proof-of-concept: MC1R agonism safely induces eumelanin in humans. The concept was proven, and the molecule went on to become an approved drug under a different name. As a research compound, MT-I's Phase I data is solid but limited in scope.

For readers considering Melanotan I, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Melanotan I

Further Reading and Resources

If you want to go deeper on Melanotan I, the evidence landscape for tanning & melanocortin peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Tanning & Melanocortin Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Melanotan I — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Levine, N., et al. (1991). "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin." JAMA, 266(19), 2730–2736. PMID 2008047
2. Dorr, R. T., et al. (2004). "Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers." Arch Dermatol, 140(7), 827–835. PMID 15262693
3. Dorr, R. T., et al. (2000). "Pharmacokinetics and pharmacodynamics of Melanotan-I." Peptides, 21(4), 587–592. PMID 10626131

---